(Total Views: 495)
Posted On: 09/29/2022 7:04:19 AM
Post# of 156402
Quote:
Having patient recover from All sorts of ailments because of leronlimab is the kind of PR we need on a regular basis.
The company can't announce it after the slap down by the FDA but Cytodyn can't control what patients and their families say. With the lack of any substantive news and sabotaging outside news it's like they don't realize how share price affects dilution or lack of news can erode shareholder confidence.
(3)
(0)
